Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
Feature|Articles|April 7, 2026
ACIP Changes Disrupt Vaccine Coverage Pipeline, Raise Cost Concerns
Author(s)Giuliana Grossi
Fact checked by: Christina Mattina
ACIP changes threaten vaccine coverage and raise costs, according to a roundtable of experts warning of widening disparities and long-term public health risks.
Advertisement
Advertisement
For decades, the CDC Advisory Committee on Immunization Practices (ACIP) served as the linchpin of pediatric vaccine policy, and by extension, the basis on which insurers determined what they would cover. When ACIP recommended a vaccine, coverage followed. That equation is now broken, and the financial fallout will be felt most acutely by families least equipped to absorb it, according to a panel of experts.
Related to this article
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
Advertisement
Advertisement